This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Email citation

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Clinical Trial

. 2017 Oct;124(10):1565-1566.

doi: 10.1016/j.ophtha.2017.04.022. Epub 2017 May 17.

Long-term Safety and Efficacy of a Sustained-Release Bimatoprost Ocular Ring

James D Brandt¹, Harvey B DuBiner², Robert Benza³, Kenneth N Sall⁴, Gary A Walker⁵, Charles P Semba⁵; Collaborators

Collaborators, Affiliations

Collaborators

Collaborators:
Donald Budenz, Douglas Day, Brian Flowers, Steven Lee, Quang Nguyen, David Wirta

Affiliations

¹ University of California - Davis, Davis, California. Electronic address: jdbrandt@ucdavis.edu.
² Clayton Eye Center, Morrow, Georgia.
³ Apex Eye, Cincinnati, Ohio.
⁴ Sall Research Medical Center, Artesia, California.
⁵ ForSight VISION5, Inc., Menlo Park, California.

PMID: 28528010
DOI: 10.1016/j.ophtha.2017.04.022

Free article

Clinical Trial

Long-term Safety and Efficacy of a Sustained-Release Bimatoprost Ocular Ring

James D Brandt et al. Ophthalmology. 2017 Oct.

Free article

. 2017 Oct;124(10):1565-1566.

doi: 10.1016/j.ophtha.2017.04.022. Epub 2017 May 17.

Authors

James D Brandt¹, Harvey B DuBiner², Robert Benza³, Kenneth N Sall⁴, Gary A Walker⁵, Charles P Semba⁵; Collaborators

Collaborators

Collaborators:
Donald Budenz, Douglas Day, Brian Flowers, Steven Lee, Quang Nguyen, David Wirta

Affiliations

¹ University of California - Davis, Davis, California. Electronic address: jdbrandt@ucdavis.edu.
² Clayton Eye Center, Morrow, Georgia.
³ Apex Eye, Cincinnati, Ohio.
⁴ Sall Research Medical Center, Artesia, California.
⁵ ForSight VISION5, Inc., Menlo Park, California.

PMID: 28528010
DOI: 10.1016/j.ophtha.2017.04.022

No abstract available

PubMed Disclaimer

Similar articles

Effects of Topical Bimatoprost 0.01% and Timolol 0.5% on Circadian IOP, Blood Pressure and Perfusion Pressure in Patients with Glaucoma or Ocular Hypertension: A Randomized, Double Masked, Placebo-Controlled Clinical Trial.
Oddone F, Rossetti L, Tanga L, Berardo F, Ferrazza M, Michelessi M, Roberti G, Manni G, Centofanti M. Oddone F, et al. PLoS One. 2015 Oct 20;10(10):e0140601. doi: 10.1371/journal.pone.0140601. eCollection 2015. PLoS One. 2015. PMID: 26484767 Free PMC article. Clinical Trial.
Durysta - a bimatoprost implant for glaucoma.
[No authors listed] [No authors listed] Med Lett Drugs Ther. 2020 Jul 27;62(1603):116-117. Med Lett Drugs Ther. 2020. PMID: 32728012 No abstract available.
Twelve-month, randomized, controlled trial of bimatoprost 0.01%, 0.0125%, and 0.03% in patients with glaucoma or ocular hypertension.
Katz LJ, Cohen JS, Batoosingh AL, Felix C, Shu V, Schiffman RM. Katz LJ, et al. Am J Ophthalmol. 2010 Apr;149(4):661-671.e1. doi: 10.1016/j.ajo.2009.12.003. Am J Ophthalmol. 2010. PMID: 20346780 Clinical Trial.
Sustained drug delivery for glaucoma: current data and future trends.
Aref AA. Aref AA. Curr Opin Ophthalmol. 2017 Mar;28(2):169-174. doi: 10.1097/ICU.0000000000000334. Curr Opin Ophthalmol. 2017. PMID: 27764023 Review.
Novel Glaucoma Drug Delivery Devices.
Lin MM, Ciolino JB, Pasquale LR. Lin MM, et al. Int Ophthalmol Clin. 2017 Fall;57(4):57-71. doi: 10.1097/IIO.0000000000000190. Int Ophthalmol Clin. 2017. PMID: 28885247 Review. No abstract available.

See all similar articles

Cited by

Drug Delivery Systems for Glaucoma: A Narrative Review.
Fea AM, Vallino V, Cossu M, Marica V, Novarese C, Reibaldi M, Petrillo F. Fea AM, et al. Pharmaceuticals (Basel). 2024 Sep 2;17(9):1163. doi: 10.3390/ph17091163. Pharmaceuticals (Basel). 2024. PMID: 39338326 Free PMC article. Review.
24-Month Phase I/II Clinical Trial of Bimatoprost Sustained-Release Implant (Bimatoprost SR) in Glaucoma Patients.
Craven ER, Walters T, Christie WC, Day DG, Lewis RA, Goodkin ML, Chen M, Wangsadipura V, Robinson MR, Bejanian M; Bimatoprost SR Study Group. Craven ER, et al. Drugs. 2020 Feb;80(2):167-179. doi: 10.1007/s40265-019-01248-0. Drugs. 2020. PMID: 31884564 Free PMC article. Clinical Trial.
Therapeutic strategies for glaucoma and optic neuropathies.
Lo J, Mehta K, Dhillon A, Huang YK, Luo Z, Nam MH, Al Diri I, Chang KC. Lo J, et al. Mol Aspects Med. 2023 Dec;94:101219. doi: 10.1016/j.mam.2023.101219. Epub 2023 Oct 13. Mol Aspects Med. 2023. PMID: 37839232 Free PMC article. Review.
Miniaturization in Glaucoma Monitoring and Treatment: A Review of New Technologies That Require a Minimal Surgical Approach.
Dick HB, Schultz T, Gerste RD. Dick HB, et al. Ophthalmol Ther. 2019 Mar;8(1):19-30. doi: 10.1007/s40123-019-0161-2. Epub 2019 Feb 6. Ophthalmol Ther. 2019. PMID: 30725339 Free PMC article. Review.
Ocular Drug Delivery: a Comprehensive Review.
Ahmed S, Amin MM, Sayed S. Ahmed S, et al. AAPS PharmSciTech. 2023 Feb 14;24(2):66. doi: 10.1208/s12249-023-02516-9. AAPS PharmSciTech. 2023. PMID: 36788150 Review.

See all "Cited by" articles

Publication types

Actions
Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

Associated data

Actions
- Search in PubMed
- Search in ClinicalTrials.gov

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information